- Home
- Products
- Customized ADCs
- IL1B
- Anti-IL1B (Gevokizumab)-MC-MMAF ADC
Anti-IL1B (Gevokizumab)-MC-MMAF ADC (CAT#: ADC-W-1330)
This ADC product is comprised of an anti-IL1B monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL1B
- Alternative Names
- IL1B; interleukin 1, beta; interleukin-1 beta; IL 1B; IL1 BETA; IL1F2; IL-1 beta; catabolin; preinterleukin 1 beta; pro-interleukin-1-beta; IL-1; IL1-BETA;
- Target Entrez Gene ID
- 3553
- Target UniProt ID
- P01584
- Overview
- The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine is produced by activated macrophages as a proprotein, which is proteolytically processed to its active form by caspase 1 (CASP1/ICE). This cytokine is an important mediator of the inflammatory response, and is involved in a variety of cellular activities, including cell proliferation, differentiation, and apoptosis. The induction of cyclooxygenase-2 (PTGS2/COX2) by this cytokine in the central nervous system (CNS) is found to contribute to inflammatory pain hypersensitivity. This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2.
- Overview
- Humanized Anti-IL1B IgG2-kappa antibody, Gevokizumab
- Generic name
- Gevokizumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD40LG (Ruplizumab)-SMCC-DM1 ADC (CAT#: ADC-W-914)
- Anti-SOST (Blosozumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1769)
- Anti-HGF (Ficlatuzumab)-SMCC-DM1 ADC (CAT#: ADC-W-1196)
- Anti-SDC1 (Indatuximab )-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2514)
- Anti-FOLH1 (MLN591)-Mc-VC-MMAE ADC (CAT#: ADC-W-432)
- Anti-IL6 (Enlimomab)-SMCC-DM1 ADC (CAT#: ADC-W-2246)
- Anti-LAMP1 (clone chMAb3)-SPDB-DM4 ADC (CAT#: ADC-W-100)
- Anti-TGFB2 (Lerdelimumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1812)
- Anti-CD74 (clone HuMax)-Mc-VC-PABC-MMAF ADC (CAT#: ADC-W-377)
- Anti-IL17RA (Ixekizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1325)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1330. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1332 | Anti-IL1B (Gevokizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-1331 | Anti-IL1B (Gevokizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-1339 | Anti-IL1B (Canakinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-1334 | Anti-IL1B (Canakinumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-1335 | Anti-IL1B (Canakinumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-493 | Anti-CD19 (clone huB4)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-491 | Anti-TNFRSF17-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
CAT# | Product Name | Linker | Payload |
ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.